BridgeBio Pharma has spun its Rolodex to fund a subset of its sprawling list of opportunities. Busy with launch and ...

CG Oncology’s late-stage bladder cancer treatment notched a complete response in roughly three-quarters of treated patients, ...

Amgen is axing obesity candidate AMG 786 and going all in on later-stage asset MariTide. | Amgen is axing obesity candidate ...

The next frontier for pharma in the obesity space is improving the quality of weight loss. | The next frontier for pharma in ...

Much of Moderna’s focus is on nabbing FDA approval for a respiratory syncytial virus vaccine, a decision expected in a matter ...

We really didn't want to have to create another Layoff Tracker this year. But here we are, launching the third annual iteration tracking industry layoffs. Last year, we tallied 187 total layoffs ...

With much still to discover in the massive world of radiopharmaceuticals, Novartis will take a deep dive into the unknown ...

Earlier this year, Metagenomi had the spotlight with a $93.7 million IPO. Now, Moderna is exiting stage left on a partnership ...

Philips has reached a $1.1 billion agreement to settle claims from about 58,000 people stemming from its yearslong recall of ...

Pfizer’s 2024 revival tour is off and running, but the Big Pharma remains mum on one critical component of its future: ...

Bristol Myers Squibb is placing a $65 million bet on Repertoire Immune Medicines’ approach to resetting the immune system. | ...

The FDA has finalized its regulatory rule that aims to bring laboratory-developed tests more in-line with how the agency ...